FRO vs NOV

Frontline plc presents a dichotomy between explosive growth and deteriorating execution. While the Piotroski F-Score of 4/9 indicates stable financial health, the company has failed to beat earnings estimates in the last four consecutive quarters, with an average surprise of -21.01%. The stock is trading significantly above its Graham Number ($20.77), suggesting a premium valuation that is not fully supported by its PEG ratio of 5.58. Despite strong operating margins and a healthy dividend, the technical trend is severely bearish (10/100), indicating a potential correction following a massive 1-year run-up.

NOV exhibits a stark divergence between operational health and financial performance. While the Piotroski F-Score of 8/9 indicates strong underlying balance sheet health and liquidity, the company is struggling with razor-thin profit margins (1.05%) and a catastrophic dividend payout ratio of 210%. The stock is trading at a significant premium to its Graham Number ($9.89) and Intrinsic Value ($1.75), suggesting the market is pricing in a recovery that is not yet reflected in the negative YoY revenue and earnings growth. Overall, the strong solvency provides a safety net, but the lack of earnings beats and bearish technicals limit upside potential.